Suppr超能文献

与 Bonebridge 和 Osia 骨传导植入设备相关的不良事件。

Adverse events associated with Bonebridge and Osia bone conduction implant devices.

机构信息

Division of Otolaryngology-Head & Neck Surgery, George Washington University School of Medicine & Health Sciences, Washington, DC, United States of America.

Division of Otolaryngology-Head & Neck Surgery, George Washington University School of Medicine & Health Sciences, Washington, DC, United States of America.

出版信息

Am J Otolaryngol. 2021 Jul-Aug;42(4):102968. doi: 10.1016/j.amjoto.2021.102968. Epub 2021 Feb 26.

Abstract

PURPOSE

Active transcutaneous Bone Conduction Implants (BCIs) are relatively new to the market and may offer improved outcomes while reducing skin-related complications associated with previous models. The purpose of this study is to examine medical device reports (MDRs) submitted to the Food and Drug Administration's (FDA) Manufacturer and User Device Facility Experience (MAUDE) database to identify adverse events with the active, transcutaneous BCIs, Bonebridge and Osia.

METHODS

A search of the FDA MAUDE database was conducted using product code "PFO" (for Active Implantable Bone Conduction Hearing System), brand names "Bonebridge" and "Osia." Data was collected on device malfunction, patient injury, inciting events, and subsequent interventions between July 1, 2018 and November 1, 2020.

RESULTS

The search query yielded 83 reports that met inclusion criteria, 56 regarding Bonebridge and 27 regarding Osia. A total of 91 adverse events were reported, including 45 device malfunctions and 46 patient injuries. Of all adverse events reported for Bonebridge, 15 (26.3%, 15/57) documented patient injuries, while the majority (73.7%, 42/57) documented device malfunctions. Of all adverse events reported for Osia, 3 (8.8%, 3/34) were reported concerning malfunctions, while 31 (91.2%, 31/34) were reported for patient injuries. The most commonly reported adverse events included lack of conduction or hearing (n = 26, 28.6%), infection (n = 14, 15.4%), and intermittent or reduced conduction or hearing (n = 12, 13.2%). From the MAUDE database reported adverse events and the total number of Osia implants given to us from Cochlear over this 28 month period, we estimate patient injuries to occur in roughly 2.1% of patients.

CONCLUSION

There are limitations to the database which make systemic analysis challenging. This study suggests that patients with transcutaneous, active BCIs may be experiencing fewer soft tissue injuries, but similar device malfunctions as those with previous models.

摘要

目的

主动经皮骨导植入物(BCI)在市场上相对较新,它们可能提供改善的结果,同时减少与以前模型相关的皮肤并发症。本研究的目的是检查向食品和药物管理局(FDA)制造商和用户设备设施经验(MAUDE)数据库提交的医疗设备报告(MDR),以确定主动经皮 BCI Bonebridge 和 Osia 的不良事件。

方法

使用产品代码“PFO”(用于主动可植入骨导听力系统)、品牌名称“Bonebridge”和“Osia”在 FDA MAUDE 数据库中进行搜索。收集了 2018 年 7 月 1 日至 2020 年 11 月 1 日期间设备故障、患者损伤、引发事件和后续干预的数据。

结果

搜索查询产生了 83 份符合纳入标准的报告,其中 56 份涉及 Bonebridge,27 份涉及 Osia。共报告了 91 起不良事件,包括 45 起设备故障和 46 起患者损伤。在报告的所有 Bonebridge 不良事件中,15 起(26.3%,15/57)记录了患者损伤,而大多数(73.7%,42/57)记录了设备故障。在报告的所有 Osia 不良事件中,3 起(8.8%,3/34)报告了故障,而 31 起(91.2%,31/34)报告了患者损伤。最常报告的不良事件包括传导或听力丧失(n=26,28.6%)、感染(n=14,15.4%)和间歇性或传导或听力降低(n=12,13.2%)。根据 MAUDE 数据库报告的不良事件和 Cochlear 在这 28 个月期间提供给我们的 Osia 植入物总数,我们估计患者损伤发生在大约 2.1%的患者中。

结论

数据库存在限制,使系统分析具有挑战性。本研究表明,接受经皮主动 BCI 的患者可能经历较少的软组织损伤,但与以前的模型一样,也会经历类似的设备故障。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验